Gene: Cyp4a2 (cytochrome P450, family 4, subfamily a, polypeptide 2)
Rattus norvegicus |
| Symbol: |
Cyp4a2
|
| Name: |
cytochrome P450, family 4, subfamily a, polypeptide 2
|
| Description: |
ENCODES a protein that exhibits alkane 1-monooxygenase activity; arachidonic acid binding; arachidonic acid monooxygenase activity; INVOLVED IN arachidonic acid metabolic process; icosanoid biosynthetic process; kidney development; PARTICIPATES IN cytochrome P450 monooxygenase mediated pathway of arachidonic acid metabolism; linoleic acid metabolic pathway; arachidonic acid metabolic pathway; ASSOCIATED WITH Polycystic Kidney, Autosomal Recessive; FOUND IN intracellular membrane-bounded organelle; INTERACTS WITH 2,2,2-tetramine; 2,3,7,8-tetrachlorodibenzodioxine; ammonium chloride |
| Type: |
protein-coding
|
| RefSeq Status: |
PROVISIONAL
|
| Also known as: |
Cyp4a11; CYPIVA2; cytochrome P-450 K-2; cytochrome P450 4A2; cytochrome P450 4A2-like; cytochrome P450 K-5; cytochrome P450, family 4, subfamily a, polypeptide 2; cytochrome P450, subfamily 4A, polypeptide 11; Cytochrome P450, subfamily IVA, polypeptide 11; cytochrome P450, subfamily IVA, polypeptide 11; cytochrome P450-LA-omega 2; lauric acid omega-hydroxylase; LOC100365231; P-450 IV4AII; P-450 IV4AII; P-450 K-2; P450 K-5; P450-LA-omega 2
|
| Allele / Splice: |
Cyp4a2em1Mcwi
|
| Latest Assembly: |
RGSC Genome Assembly v3.4
|
| NCBI Annotation Information: |
Annotation category: suggests misassembly |
| Position: |
| Map | Chr | Position | Strand | Source |
|---|
Rat Cytogenetic Map | 5 | q36 | | NCBI | RGSC Genome Assembly v5.0 | 5 | 137,989,327 - 138,000,280 | - | NCBI | RGSC Genome Assembly v3.4 | 5 | 135,765,673 - 135,773,006 | - | NCBI | Genome Assembly 3.1 | 5 | 135,553,026 - 135,778,567 | - | NCBI |
|
| Model |
|
 Disease Annotations |
 Gene-Chemical Interaction Annotations
| 2,2,2-tetramine | multiple interactions | EXP | | 6480464 | Trientine promotes the reaction [Streptozocin results in decreased expression of CYP4A2 protein] | CTD | PMID:19634143 | | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP4A2 mRNA | CTD | PMID:22659317 | | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of CYP4A2 mRNA | CTD | PMID:16483693 | | Aroclor 1254 | increases expression | EXP | | 6480464 | Chlorodiphenyl (54% Chlorine) results in increased expression of CYP4A2 mRNA | CTD | PMID:22659317 | | bis(2-ethylhexyl) phthalate | increases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in increased expression of CYP4A2 mRNA | CTD | PMID:11752103 | | clofibrate | increases expression | EXP | | 6480464 | Clofibrate results in increased expression of CYP4A2 mRNA | CTD | PMID:2766933 PMID:11328961 | | clofibrate | increases expression | EXP | | 6480464 | Clofibrate results in increased expression of CYP4A2 mRNA | CTD | PMID:11328961 PMID:2766933 | | clofibrate | increases expression | EXP | | 6480464 | Clofibrate results in increased expression of CYP4A2 mRNA | CTD | PMID:11328961 | | clofibrate | multiple interactions | ISO | | 6480464 | PPARA affects the reaction [Clofibrate results in increased expression of CYP4A2 mRNA] | CTD | PMID:10787435 | | clofibrate | increases expression | ISO | | 6480464 | Clofibrate results in increased expression of CYP4A2 mRNA | CTD | PMID:10787435 | | clofibric acid | increases expression | EXP | | 6480464 | Clofibric Acid results in increased expression of CYP4A2 mRNA | CTD | PMID:11752103 more ... | | clofibric acid | increases expression | EXP | | 6480464 | Clofibric Acid results in increased expression of CYP4A2 mRNA | CTD | PMID:11752103 more ... | | clofibric acid | increases expression | EXP | | 6480464 | Clofibric Acid results in increased expression of CYP4A2 mRNA | CTD | PMID:10772642 more ... | | farnesol | increases activity | EXP | | 6480464 | Farnesol results in increased activity of CYP4A2 protein | CTD | PMID:15840382 | | gemfibrozil | increases expression | EXP | | 6480464 | Gemfibrozil results in increased expression of CYP4A2 mRNA | CTD | PMID:10787435 | | lauric acid | affects metabolic processing | EXP | | 6480464 | CYP4A2 protein affects the metabolism of lauric acid | CTD | PMID:15879494 | | orotic acid | multiple interactions | EXP | | 6480464 | [Sucrose co-treated with Orotic Acid] results in increased expression of CYP4A2 mRNA | CTD | PMID:15670589 | | perfluorodecanoic acid | increases expression | EXP | | 6480464 | perfluorodecanoic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:11752103 | | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:19162173 | | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:19162173 | | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:10787435 PMID:19162173 | | pirinixic acid | increases expression | ISO | | 6480464 | pirinixic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:10787435 | | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of CYP4A2 mRNA | CTD | PMID:19162173 PMID:10787435 | | pirinixic acid | multiple interactions | ISO | | 6480464 | PPARA affects the reaction [pirinixic acid results in increased expression of CYP4A2 mRNA] | CTD | PMID:10787435 | | pregnenolone 16alpha-carbonitrile | decreases expression | EXP | | 6480464 | Pregnenolone Carbonitrile results in decreased expression of CYP4A2 mRNA | CTD | PMID:19162173 | | rosiglitazone | increases expression | EXP | | 6480464 | rosiglitazone results in increased expression of CYP4A2 mRNA | CTD | PMID:21515302 | | streptozocin | decreases expression | EXP | | 6480464 | Streptozocin results in decreased expression of CYP4A2 protein | CTD | PMID:19634143 | | streptozocin | multiple interactions | EXP | | 6480464 | Trientine promotes the reaction [Streptozocin results in decreased expression of CYP4A2 protein] | CTD | PMID:19634143 | | sucrose | multiple interactions | EXP | | 6480464 | [Sucrose co-treated with Orotic Acid] results in increased expression of CYP4A2 mRNA | CTD | PMID:15670589 | | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of CYP4A2 protein | CTD | PMID:17606319 | | triclosan | increases expression | EXP | | 6480464 | Triclosan results in increased expression of CYP4A2 mRNA | CTD | PMID:22659317 | | troglitazone | increases expression | EXP | | 6480464 | troglitazone results in increased expression of CYP4A2 mRNA | CTD | PMID:21515302 | | zinc atom | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of CYP4A2 mRNA | CTD | PMID:12672911 PMID:15671213 | | zinc(0) | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of CYP4A2 mRNA | CTD | PMID:12672911 PMID:15671213 | |
| 70212 | Niddm25 | Non-insulin dependent diabetes mellitus QTL 25 | 3.54 | | Glucose level | fasting | 5 | 1 | 138272129 | Rat |
| 1578766 | Tcas11 | Tongue tumor susceptibility QTL 11 | 4.12 | | Tongue tumor susceptibility | tongue tumor number | 5 | 17517235 | 168005953 | Rat |
| 2290448 | Scl54 | Serum cholesterol level QTL 54 | 2.93 | | Lipid level | cholesterol level | 5 | 32701659 | 138272129 | Rat |
| 1641912 | Alcrsp18 | Alcohol response QTL 18 | | | Alcohol response | loss of righting reflex | 5 | 36386126 | 148460381 | Rat |
| 1549845 | Scl44 | Serum cholesterol level QTL 44 | 6 | | Lipid level | serum cholesterol, post dietary | 5 | 41498818 | 155121024 | Rat |
| 1331801 | Rf33 | Renal function QTL 33 | 4.149 | | Renal function | renal vascular resistance | 5 | 45499364 | 135916908 | Rat |
| 1576312 | Emca8 | Estrogen-induced mammary cancer QTL 8 | 4.1 | | Mammary tumor susceptibility | estradiol-induced | 5 | 52434178 | 148460381 | Rat |
| 70189 | Mcs5 | Mammary carcinoma susceptibility QTL 5 | 10.51 | | Mammary tumor susceptibility | | 5 | 58063971 | 139156771 | Rat |
| 61426 | Scl2 | Serum cholesterol level QTL 2 | 7.3 | .001 | Lipid level | cholesterol | 5 | 62098646 | 149757440 | Rat |
| 61393 | Bp7 | Blood pressure QTL 7 | 4.5 | .0001 | Blood pressure | salt-loaded systolic | 5 | 62555131 | 168174140 | Rat |
| 1354598 | Srn6 | Serum renin concentration QTL 6 | 3.8 | | Renin concentration | serum | 5 | 71971592 | 157597184 | Rat |
| 1302790 | Scl20 | Serum cholesterol QTL 20 | 6.4 | .0001 | Lipid level | cholesterol level | 5 | 86116638 | 172913795 | Rat |
| 1300122 | Wbc1 | White blood cell count QTL 1 | 2.75 | | White blood cell count | salt-loaded | 5 | 89261341 | 147065912 | Rat |
| 1298086 | Bp156 | Blood pressure QTL 156 | | | Blood pressure | salt-loaded systolic | 5 | 90916908 | 135916908 | Rat |
| 6903316 | Bw113 | Body weight QTL 113 | 2 | .0103 | Body weight | | 5 | 93245548 | 138245548 | Rat |
| 631527 | Tls1 | T-lymphoma susceptibility QTL 1 | 3.5 | .001 | T-lymphoma susceptibility | propylnitrosourea induced | 5 | 94515803 | 139515803 | Rat |
| 61452 | Ciaa5 | CIA Autoantibody QTL 5 | 3.5 | | Anti-type II collagen autoantibody titer | | 5 | 99080786 | 149757440 | Rat |
| 1331796 | Thshl2 | Thyroid stimulating hormone level QTL 2 | 2.3 | | Thyroid stimulating hormone level | | 5 | 101506332 | 154014139 | Rat |
| 2317753 | Glom24 | Glomerulus QTL 24 | 3.1 | | Renal pathology | glomerulus inflammation | 5 | 102024381 | 143540180 | Rat |
| 1358187 | Emca1 | Estrogen-induced mammary cancer QTL 1 | 4.4 | | Mammary tumor susceptibility | estradiol-induced | 5 | 103677659 | 155120876 | Rat |
| 1578673 | Bmd13 | Bone mineral density QTL 13 | 4.9 | | Bone mineral density | femoral neck trabecular vBMD | 5 | 108589975 | 153589975 | Rat |
| 2317056 | Wbc3 | White blood cell count QTL 3 | 2.51 | .01 | White blood cell count | | 5 | 112840801 | 157840801 | Rat |
| 1549838 | Bss4 | Bone structure and strength QTL 4 | 9.2 | | Bone structure and strength | Femoral midshaft moment of inertia | 5 | 113689301 | 158689301 | Rat |
| 7207481 | Bss106 | Bone structure and strength QTL 106 | 7.9 | | Bone strength | Femoral ultimate force | 5 | 113689301 | 158689301 | Rat |
| 7207486 | Bss109 | Bone structure and strength QTL 109 | | | Bone strength | Femoral energy to break | 5 | 113689301 | 158689301 | Rat |
| 7207488 | Bss110 | Bone structure and strength QTL 1 | 8.4 | | Bone strength | Femoral stiffness | 5 | 113689301 | 158689301 | Rat |
| 7207491 | Bss112 | Bone structure and strength QTL 112 | 7 | | Bone structure | Femoral midshaft cortical area | 5 | 113689301 | 158689301 | Rat |
| 1298089 | Scl14 | Serum cholesterol level QTL 14 | 5.8 | .0004 | Lipid level | cholesterol | 5 | 115772027 | 160772027 | Rat |
| 1598847 | Cm62 | Cardiac mass QTL 62 | 3.4 | | Cardiac mass | | 5 | 115772027 | 160772027 | Rat |
| 1581510 | Cm54 | Cardiac mass QTL 54 | 3.4 | .05 | Cardiac mass | left ventricle | 5 | 126963761 | 150236260 | Rat |
| 2293642 | Bss37 | Bone structure and strength QTL 37 | 4.64 | .0001 | Bone strength | | 5 | 126963761 | 157597184 | Rat |
| 724525 | Bp147 | Blood pressure QTL 147 | 4.3 | .0001 | Blood pressure | systolic | 5 | 132950669 | 173096209 | Rat |
| 1598819 | Bp292 | Blood pressure QTL 292 | 4.3 | | Blood pressure | systolic | 5 | 134356746 | 173096209 | Rat |
| 1598861 | Cm64 | Cardiac mass QTL 64 | 2.9 | | Cardiac mass | | 5 | 134356746 | 173096209 | Rat |
| 1581505 | Rf54 | Renal function QTL 54 | | | Renal function | renal production of 20-HETE | 5 | 134871897 | 139996194 | Rat |